Effectiveness of highly-active antiretroviral therapy by race/ethnicity
- 13 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (11) , 1531-1538
- https://doi.org/10.1097/01.aids.0000237369.41617.0f
Abstract
To determine the effectiveness of HAART by race/ethnicity. Prospective multicenter cohort study. We studied 991 African–Americans and 911 European–Americans enrolled in the United States Military's Tri-Service AIDS Clinical Consortium Natural History Study who had dates of HIV seroconversion known within 5 years and followed between 1990 and 2002. We determined the rate of disease progression to AIDS and death for subjects in this cohort. Multivariable models evaluated race, pre-HAART (1990–1995) and HAART (1996–2002) eras, age, gender and military service. In the pre-HAART era, African–Americans had a statistically nonsignificant trend towards better outcomes: the relative hazards (RH) of AIDS and death for African–Americans compared to European–Americans were 0.85 [95% confidence interval (CI), 0.68–1.05] and 0.77 (95% CI, 0.55–1.08), respectively. In the HAART era, outcomes were similar by race: 1.17 (95% CI, 0.86–1.61) for AIDS and 1.11 (95% CI, 0.81–1.53) for death with overlapping Kaplan–Meier curves. Relative to the pre-HAART era, the adjusted RH of AIDS in the HAART era was 0.41 (95% CI, 0.31–0.54) and 0.30 (95% CI, 0.22–0.40) for African–American and European–American participants, respectively. Analogous RH for death were 0.55 (95% CI, 0.38–0.80) and 0.38 (95% CI, 0.27–0.54). The precipitous declines in AIDS and death in the HAART era were not statistically different by race. In a large multi-racial cohort with equal access to health care, HIV treatment outcomes by race/ethnicity were similar.Keywords
This publication has 28 references indexed in Scilit:
- Do Sex and Race/Ethnicity Influence CD4 Cell Response in Patients Who Achieve Virologic Suppression during Antiretroviral Therapy?Clinical Infectious Diseases, 2003
- The Effect of Race/Ethnicity on the Outcome of Highly Active Antiretroviral Therapy for Human Immunodeficiency Virus Type 1–Infected PatientsClinical Infectious Diseases, 2002
- Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapyAIDS, 2001
- Association of Race and Gender With HIV-1 RNA Levels and Immunologic ProgressionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- HIV/AIDS among African Americans: progress or progression?AIDS, 2000
- Survival after introduction of HAART in people with known duration of HIV-1 infectionThe Lancet, 2000
- Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-DAIDS, 1999
- Differential survival in blacks and Hispanics with AIDSEthnicity & Health, 1996
- Race, Sex, Drug Use, and Progression of Human Immunodeficiency Virus DiseaseNew England Journal of Medicine, 1995
- Racial and Ethnic Differences in Outcome in Zidovudine-Treated Patients With Advanced HIV DiseasePublished by American Medical Association (AMA) ,1991